Differential effect of genetic burden on disease phenotypes in crohn's disease and ulcerative colitis: Analysis of a north american cohort

American Journal of Gastroenterology

Volumn 109, Issue 3, 2014, Pages 395-400

  Ananthakrishnan, Ashwin N ^a,b   Huang, Hailiang ^a,c   Nguyen, Deanna D ^a,b   Sauk, Jenny ^a,b   Yajnik, Vijay ^a,b   Xavier, Ramnik J ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; FEMALE; GENE LOCUS; GENETIC RISK SCORE; GENETIC VARIABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SMOKING; ULCERATIVE COLITIS; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; NORTH AMERICA; PHENOTYPE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84895778869     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.464     Document Type: Article

References (23)

1. Loft us EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
2. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54 e42; quiz e30.
3. Van Assche G, Lewis JD, Lichtenstein ein GR et al. The London position statement of the World Congress of Gastroenterology on Biological Th erapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106: 1594-602;; quiz 1593, 1603.
4. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
5. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
6. Afif W, Loft us EV Jr. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am 2009; 38: 691-709.
7. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
8. Jung C, Colombel JF, Lemann M et al. Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PLoS One 2012; 7: e52223.
9. Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis 2013; 19: 2021-30.
10. Chibnik LB, Keenan BT, Cui J et al. Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset. PLoS One 2011; 6: e24380.
11. Kurreeman F, Liao K, Chibnik L et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet 2011; 88: 57-69.
12. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Th er 2011; 13: 101.
13. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
14. Adler J, Rangwalla SC, Dwamena BA et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011; 106: 699-712.
15. Rivas MA, Beaudoin M, Gardet A et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-73.
16. Weersma RK, Stokkers PC, van Bodegraven AA et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009; 58: 388-95.
17. Abreu MT, Taylor KD, Lin YC et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123: 679-88.
18. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854-66.
19. Annese V, Lombardi G, Perri F et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol 2005; 100: 84-92.
20. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17.
21. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78.
22. Nimmo ER, Prendergast JG, Aldhous MC et al. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th 17 pathway. Inflamm Bowel Dis 2012; 18: 889-99.
23. Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can J Gastroenterol 2012; 26: 909-15.